Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Andrew Aplin and Vivian Chua.
Connection Strength

4.474
  1. Chua V, Han A, Bechtel N, Purwin TJ, Hunter E, Liao C, Harbour JW, Aplin AE. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma. Pigment Cell Melanoma Res. 2021 Aug 04.
    View in: PubMed
    Score: 0.984
  2. Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med. 2019 Feb; 11(2).
    View in: PubMed
    Score: 0.827
  3. Chua V, Aplin AE. Novel therapeutic strategies and targets in advanced uveal melanoma. Curr Opin Oncol. 2018 Mar; 30(2):134-141.
    View in: PubMed
    Score: 0.776
  4. Chua V, Lapadula D, Randolph C, Benovic JL, Wedegaertner PB, Aplin AE. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma. Mol Cancer Res. 2017 May; 15(5):501-506.
    View in: PubMed
    Score: 0.723
  5. Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, Harbour JW, Aplin AE. Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. Oncogene. 2021 Mar; 40(9):1753.
    View in: PubMed
    Score: 0.239
  6. Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, William Harbour J, Aplin AE. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. Oncogene. 2020 Nov 18.
    View in: PubMed
    Score: 0.234
  7. Chua V, Mattei J, Han A, Johnston L, LiPira K, Selig SM, Carvajal RD, Aplin AE, Patel SP. The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019). Clin Cancer Res. 2021 Jan 01; 27(1):28-33.
    View in: PubMed
    Score: 0.233
  8. Teh JL, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso JA, Aplin AE. Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma. Mol Cancer Ther. 2020 May 19.
    View in: PubMed
    Score: 0.226
  9. Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol Cancer Ther. 2017 Mar; 16(3):516-528.
    View in: PubMed
    Score: 0.180
  10. Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK. Inhibition of NF-?B-dependent signaling enhances sensitivity and overcomes resistance to BET inhibition in uveal melanoma. Cancer Res. 2019 Mar 18.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.